Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alnylam Pharmaceuticals
Biotech
Roche sees Alnylam RNAi drug flunk trial, still plans phase 3
The hypertension med zilebesiran failed to hit the primary endpoint of the last in a trio of midstage studies.
James Waldron
Sep 1, 2025 4:39am
City Tx breaks ground with $135M, blueprints from Maraganore
Oct 8, 2024 10:38am
Roche, Alnylam celebrate second ph. 2 win for blood pressure med
Mar 5, 2024 9:05am
Agios' next-up PK med quelled transfusion need in some patients
Nov 20, 2023 11:24am
Roche's bet pays off as Alnylam hypertension med hits in phase 2
Sep 7, 2023 8:55am
BridgeBio lifts the hood on phase 3 acoramidis data
Aug 28, 2023 11:21am
